Losigamone: A putative antiepileptic drug

Journal of Epilepsy

Volumn 10, Issue 2, 1997, Pages 62-66

  Morris III, George L ^a,f   Collins, Susan ^a   Bell, Walter ^b   Sahlroot, J Todd ^c   Matula, Margaret ^d   Cereghino, James J ^e  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b N Institutes of N Disorders Stroke   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d Division of AIDS   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f NONE   (United States)

Author keywords

Antiepileptic drugs; Controlled clinical trial; Drug toxicity; Losigamone; Partial seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; LOSIGAMONE; PHENYTOIN;

ADULT; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MEAN RESIDENCE TIME; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031552134     PISSN: 08966974     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6974(96)00085-0     Document Type: Article

References (8)

1. 1. Stein U, Klessing K, Chaterjee SS. Losigamone. Epilepsy Res 1991;(suppl 3):129-133.
2. 2. Swinyard EA, Wolf HH, Franklin MR, et al. The profile of anticonvulsant activity and acute toxicity of 137021, 137022, and some prototype antiepileptic drugs in mice and rats. The early evaluation of anticonvulsant drugs (Red Book, 12/5/88). Unpublished report from the Epilepsy Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
3. 3. Kelly KM, Macdonald RL. Losigamone (AO-33) reduces high-threshold calcium currents in rat dorsal root ganglion neurons. Epilepsia 1993;34(suppl 6):118.
4. 4. Lücker PW. Ascending dose tolerance and pharmacokinetic study of AO-33 in healthy male volunteers. Unpublished report on file, December 1988, Dr. Willmar Schwabe GmbH & Co.
5. 5. Lücker PW. Repeated dose tolerance and pharmacokinetic study of AO-33 in healthy male volunteers. Unpublished report on file. March 1989, Dr. Willmar Schwabe GmbH & Co.
6. 6. Lücker PW. Double-blind, placebo-controlled, repeated dose tolerance and pharmacokinetic study of Losigamone in healthy volunteers. Unpublished report on file. July 1992, Dr. Willmar Schwabe GmbH & Co.
7. 7. Dienel A, Biber A, Klessing K, Stein U. Losigamone: first clinical results. Epilepsia 1992;33(suppl 3):81.
8. A receptor system. Epilepsia 1995;36(10):983-989.